S&CO Inc. Has $2.52 Million Position in Elanco Animal Health Incorporated $ELAN

S&CO Inc. lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 21.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,284 shares of the company’s stock after selling 30,000 shares during the period. S&CO Inc.’s holdings in Elanco Animal Health were worth $2,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Northwestern Mutual Investment Management Company LLC increased its holdings in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after purchasing an additional 428 shares in the last quarter. Legacy Capital Group California Inc. increased its position in Elanco Animal Health by 3.1% in the 4th quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company’s stock valued at $475,000 after acquiring an additional 632 shares during the period. AlphaQuest LLC increased its position in Elanco Animal Health by 13.7% in the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after acquiring an additional 718 shares during the period. Jones Financial Companies Lllp increased its position in Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after acquiring an additional 798 shares during the period. Finally, US Bancorp DE increased its position in Elanco Animal Health by 1.9% in the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after acquiring an additional 824 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Leerink Partners upped their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Morgan Stanley increased their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. Finally, Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $28.20.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $19.85 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The business has a 50-day moving average price of $23.31 and a two-hundred day moving average price of $23.33. Elanco Animal Health Incorporated has a 1-year low of $12.40 and a 1-year high of $27.72. The company has a market cap of $9.92 billion, a P/E ratio of -39.71, a PEG ratio of 2.31 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter last year, the firm posted $0.37 earnings per share. The firm’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.